Abstract:Today, persistent and uncontrolled inflammation is appreciated to play a pivotal role in many diseases, such as cardiovascular diseases, neurodegenerative diseases, metabolic syndrome and many other diseases of public health concern (e.g. Coronavirus Disease 2019 (COVID-19) and periodontal disease). The ideal response to initial challenge in humans is a self-limited inflammatory response leading to complete resolution. The resolution phase is now widely recognized as a biosynthetically active process, governed by a superfamily of endogenous chemical mediators that stimulate resolution of inflammatory responses, namely specialized proresolving mediators (SPMs). Because resolution is the natural ideal response, the SPMs have gained attention. SPMs are mediators that include ω-6 arachidonic acid-derived lipoxins, ω-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)-derived resolvins, protectins and maresins, cysteinyl-SPMs, as well as n-3 docosapentaenoic acid (DPA)-derived SPMs. These novel immunoresolvents, their biosynthetic pathways and receptors have proven to promote resolution of inflammation, clearance of microbes, reduce pain and promote tissue regeneration via specific cellular and molecular mechanisms. As of 17 August, 2020, PubMed.gov reported >1170 publications for resolvins, confirming their potent protective actions from many laboratories worldwide. Since this field is rapidly expanding, we provide a short update of advances within 2-3 years from human and preclinical animal studies, together with the structural-functional elucidation of SPMs and identification of novel SPM receptors. These new discoveries indicate that SPMs, their pathways and receptors could provide a basis for new approaches for treating inflammation-associated diseases and for stimulating tissue regeneration via resolution pharmacology and precision nutrition.

Resolution medicine in cancer, infection, pain and inflammation: are we on track to address the next Pandemic?

Specialized pro-resolving mediator network: an update on production and actions

Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators

Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease

New Advances in Targeting the Resolution of Inflammation: Implications for Specialized Pro-Resolving Mediator GPCR Drug Discovery

Advance in Pro-Resolution Lipid Mediators and Mechanisms of Inflammation Resolution

Resolvins, Specialized Proresolving Lipid Mediators, and Their Potential Roles in Metabolic Diseases

Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus

Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy

Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer

Resolution pharmacology and the treatment of infectious diseases

Resolution of chronic inflammation and cancer

Anti-inflammatory lipid mediators and insights into the resolution of inflammation

Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease

Low-dose pro-resolving mediators temporally reset the resolution response to microbial inflammation

Pro-resolving lipid mediators are leads for resolution physiology

Inflammation Resolution in the Cardiovascular System: Arterial Hypertension, Atherosclerosis, and Ischemic Heart Disease

Design of nanoformulation of specialized pro-resolving mediators to facilitate inflammation resolution and disease treatment

Resolution of Inflammation: A New Paradigm for the Pathogenesis of Periodontal Diseases

Specialized pro-resolving mediators - Key players in resolution

Resolvins and protectins in the termination program of acute inflammation